This study looked at how people who have had heart attacks understand their risk of getting diabetes. The researchers studied 466 heart attack patients in Augsburg, Germany, and found some concerning results.
This study analyzed the potential protective effects of metformin, a common diabetes medication, on non-melanoma skin cancers (NMSC) — basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) — using a large and diverse U.S. health database called All of Us. Skin cancer poses significant risks, particularly in patients with darker skin tones, due to delayed diagnosis and unique risk factors. For example, SCC in African American patients has a much higher metastasis risk (20-40%) compared to sun-induced SCCs in Caucasian populations (1-4%).
Empagliflozin is a medication primarily used for diabetes treatment, but researchers have investigated its effects on uric acid levels in people with chronic kidney disease (CKD) through the EMPA-KIDNEY trial. This extensive study involved 6,609 patients with CKD, examining how empagliflozin affects uric acid levels, a naturally occurring substance that can cause gout when elevated. The trial was designed to compare patients taking empagliflozin against those taking a placebo over approximately two years. The researchers collected detailed data about kidney function, uric acid levels, and various other health markers throughout the study period.
Researchers conducted a study to understand if the diabetes medication empagliflozin affects eye problems (specifically diabetic retinopathy) in people with type 2 diabetes. Diabetic retinopathy is a condition where high blood sugar damages the blood vessels in the back of the eye, potentially leading to vision loss.
People with diabetes or prediabetes face an elevated risk of developing various cardiovascular conditions, including heart disease, stroke, and congestive heart failure. One crucial factor contributing to this increased risk is how well the body utilizes insulin, which can be measured using the estimated glucose disposal rate (eGDR). A lower eGDR score indicates a poorer ability to process insulin and is associated with a higher likelihood of developing heart-related complications.
